🚀 VC round data is live in beta, check it out!
Spero Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Spero Therapeutics and similar public comparables like Hyloris Pharmaceuticals, Molecular Partners, Tenaya Therapeutics, Tiziana Life Sciences and more.
Spero Therapeutics Overview
About Spero Therapeutics
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Founded
2013
HQ
Employees
32
Website
Sectors
Financials (LTM)
EV
$124M
Spero Therapeutics Financials
Spero Therapeutics reported last 12-month revenue of $67M.
In the same LTM period, Spero Therapeutics generated $9M in net income.
Revenue (LTM)
Spero Therapeutics P&L
In the most recent fiscal year, Spero Therapeutics reported revenue of $67M and EBITDA of $7M.
Spero Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $67M | XXX | $67M | XXX | XXX | XXX |
| EBITDA | — | XXX | $7M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $9M | XXX | $9M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Spero Therapeutics Stock Performance
Spero Therapeutics has current market cap of $161M, and enterprise value of $124M.
Market Cap Evolution
Spero Therapeutics' stock price is $2.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $124M | $161M | 2.0% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSpero Therapeutics Valuation Multiples
Spero Therapeutics trades at 1.8x EV/Revenue multiple, and 17.3x EV/EBITDA.
EV / Revenue (LTM)
Spero Therapeutics Financial Valuation Multiples
As of April 11, 2026, Spero Therapeutics has market cap of $161M and EV of $124M.
Equity research analysts estimate Spero Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spero Therapeutics has a P/E ratio of 18.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $161M | XXX | $161M | XXX | XXX | XXX |
| EV (current) | $124M | XXX | $124M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 17.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 17.3x | XXX | XXX | XXX |
| P/E | 18.8x | XXX | 18.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Spero Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Spero Therapeutics Margins & Growth Rates
Spero Therapeutics' revenue in the last fiscal year grew by 118%.
Spero Therapeutics' revenue per employee in the last FY averaged $2.1M, while opex per employee averaged $1.6M for the same period.
Spero Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 118% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (110%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 32% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 58% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Spero Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hyloris Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Molecular Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Tenaya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tiziana Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthocell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spero Therapeutics M&A Activity
Spero Therapeutics acquired XXX companies to date.
Last acquisition by Spero Therapeutics was on XXXXXXXX, XXXXX. Spero Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Spero Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSpero Therapeutics Investment Activity
Spero Therapeutics invested in XXX companies to date.
Spero Therapeutics made its latest investment on XXXXXXXX, XXXXX. Spero Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Spero Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Spero Therapeutics
| When was Spero Therapeutics founded? | Spero Therapeutics was founded in 2013. |
| Where is Spero Therapeutics headquartered? | Spero Therapeutics is headquartered in United States. |
| How many employees does Spero Therapeutics have? | As of today, Spero Therapeutics has over 32 employees. |
| Who is the CEO of Spero Therapeutics? | Spero Therapeutics' CEO is Esther Rajavelu. |
| Is Spero Therapeutics publicly listed? | Yes, Spero Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Spero Therapeutics? | Spero Therapeutics trades under SPRO ticker. |
| When did Spero Therapeutics go public? | Spero Therapeutics went public in 2017. |
| Who are competitors of Spero Therapeutics? | Spero Therapeutics main competitors are Hyloris Pharmaceuticals, Molecular Partners, Tenaya Therapeutics, Tiziana Life Sciences. |
| What is the current market cap of Spero Therapeutics? | Spero Therapeutics' current market cap is $161M. |
| What is the current revenue of Spero Therapeutics? | Spero Therapeutics' last 12 months revenue is $67M. |
| What is the current EV/Revenue multiple of Spero Therapeutics? | Current revenue multiple of Spero Therapeutics is 1.8x. |
| Is Spero Therapeutics profitable? | Yes, Spero Therapeutics is net-income-positive (as of the last 12 months). |
| What is the current net income of Spero Therapeutics? | Spero Therapeutics' last 12 months net income is $9M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.